CRVS | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 4%

Liquidity 48%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.00%

1 Month

-15.80%

3 Months

98.98%

6 Months

205.93%

1 Year

338.25%

2 Year

711.57%

Key data

Stock price

$17.53

P/E Ratio

0.00

DAY RANGE

$16.84 - $18.26

EPS

-$0.24

52 WEEK RANGE

$2.54 - $26.95

52 WEEK CHANGE

$324.46

MARKET CAP

549.168 M

YIELD

N/A

SHARES OUTSTANDING

74.682 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-05-2025

BETA

1.73

PUBLIC FLOAT

AVERAGE 10 VOLUME

$957,809

AVERAGE 30 VOLUME

$1,379,192

Company detail

CEO: Richard A. Miller
Region: US
Website: corvuspharma.com
Employees: 30
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Corvus Pharmaceuticals, Inc. focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company was incorporated in 2014 and is based in Burlingame, California.

CRVS - Corvus Pharmaceuticals, Inc.